Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis
- PMID: 41368639
- PMCID: PMC12683330
- DOI: 10.3389/fimmu.2025.1741271
Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis
Abstract
[This corrects the article DOI: 10.3389/fimmu.2021.641206.].
Keywords: Sunitinib; endometriosis; gene expressions; immunosuppression; myeloid-derived suppressor cells.
Copyright © 2025 He, Hung, Liang, Zhang, Gao, Chu, Zhang, Xu, Chung and Wang.
Erratum for
-
Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis.Front Immunol. 2021 Jul 22;12:641206. doi: 10.3389/fimmu.2021.641206. eCollection 2021. Front Immunol. 2021. PMID: 34367125 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
